We are live on ! Find out more

Corcept Therapeutics

CORT

Market cap $12.3B

113.76 USD

+3.47

3.15%

At close Updated Sep 21, 4:00 PM EDT

Pre-market

After hours

114.45

+0.69

0.61%

1 day

3.15%

5 days

1.6%

1 month

-6.94%

3 months

42.72%

6 months

238.27%

Year to date

197.8%

1 year

42.2%

5 years

461.78%

10 years

1,728.94%

About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Employees: 730

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 48%

Neutral 40%

Negative 12%

Zacks Investment Research

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined wit.

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

Zacks Investment Research

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept's Korlym sales rise 6.2% in H1 2026 as demand grows, while Lifyorli's launch offers a path to diversify revenues.

Will Korlym Continue to Aid CORT's Growth Through the Rest of 2026?

Corcept Grows to Mid-Cap on Institutional Support

Institutions keep buying Corcept Therapeutics Incorporated (CORT) shares in big volumes, sending them up 1,016% since 2017 and on the cusp of joining the S&P MidCap 400 index.

Corcept Grows to Mid-Cap on Institutional Support

Corcept: Not Cheap, But Backed By Real Structural Growth

Corcept Therapeutics is evolving into a multi-engine growth platform, driven by expanding Cushing's and a rapid oncology ramp with Lifyorli. CORT delivered strong 2Q26 results: $256.1M revenue (+32% YoY), $47.6M Lifyorli launch, and maintained profitability despite elevated launch expenses. CATALYST and MOMENTUM studies reveal Cushing's is more prevalent than previously thought, structurally expanding the addressable market and supporting multi-billion-dollar revenue potential.

Corcept: Not Cheap, But Backed By Real Structural Growth

Zacks Investment Research

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Corcept (CORT) reported earnings 30 days ago. What's next for the stock?

Why Is Corcept (CORT) Down 1.2% Since Last Earnings Report?

Like The Knick's, Corcept Rebounded And Is Crushing It

Corcept Therapeutics is rated Strong Buy with $163 one-year and $222 two-year price targets, driven by explosive revenue and margin expansion. Lifyorli's rapid launch for platinum-resistant ovarian cancer and Korlym's resilient growth underpin 44%+ revenue growth and 98% gross margins, fueling EPS leverage. Based on my Lifyorli model, Street revenue and EPS estimates could be significantly low.

Like The Knick's, Corcept Rebounded And Is Crushing It

Trump is up 230% on this stock trade since March

President Donald Trump disclosed a position in Corcept Therapeutics (NASDAQ: CORT) on March 4, when the pharmaceutical company was trading at $35.69.

Trump is up 230% on this stock trade since March

Zacks Investment Research

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Corcept Therapeutics (CORT) is a Top Momentum Stock for the Long-Term

Raised Guidance Lifts Corcept to 52-Week High

CORT discovers, develops, and sells medications to treat severe metabolic, oncologic, and psychiatric disorders, focusing on the hormone cortisol (over 1,000 proprietary modulators) as well as Cushing's syndrome.

Raised Guidance Lifts Corcept to 52-Week High

See News Rankings

Price charts implemented using Lightweight Charts™